Erik Sprengers has held numerous positions in the pharma industry, most recently as Head of Merck´s Translational Medicine Research Centre in Singapore.
Prior to that, he was VP Translational Medicine and VP Proof of Concept Team Office at the Schering-Plough Research Institute
From 1988 to 2003, Erik was responsible for both licensing and research in the Anaesthesia franchise of Organon in The Netherlands. During this period, he became involved in cyclodextrin research and initiated the program that subsequently led to the successful development of sugammadex (Bridion).
Erik Sprengers holds degrees in Chemistry and in Medicine from Utrecht University, The Netherlands, and an MBA from University of Rochester/Erasmus University Rotterdam.